GlassScriptPhysician profile
Shruti Bhandari
NPI 1497169650
$3,229.49
in general payments reported to CMS, 2019-2025
29 companies · $88.44 in 2025
The $88.44 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,554 · 2020: $488 · 2021: $12.19 · 2023: $21.00 · 2024: $65.88 · 2025: $88.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.32 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,021.48 | 2019-2020 | |
| Celgene Corporation | $263.16 | 2019 | |
| Janssen Biotech, INC. | $212.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $199.50 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $191.62 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.43 | 2019-2020 | |
| Eisai INC. | $182.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $139.73 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $106.00 | 2019 | |
| Foundation Medicine, INC. | $101.96 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $100.32 | 2019-2025 | |
| Astellas Pharma US INC | $75.99 | 2019 | |
| Genzyme Corporation | $69.53 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $65.88 | 2024 | Libtayo |
| Incyte Corporation | $34.16 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.09 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $28.92 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $27.11 | 2019-2020 | |
| Verastem, INC. | $24.28 | 2019 | |
| Daiichi Sankyo INC. | $23.12 | 2020 | |
| Puma Biotechnology, INC. | $17.36 | 2019 | |
| Seagen INC. | $16.74 | 2019 | |
| Lilly USA, LLC | $16.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.21 | 2019 | |
| Novo Nordisk INC | $15.97 | 2019 | |
| Clovis Oncology, INC. | $15.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.65 | 2020 | |
| Array Biopharma INC | $14.18 | 2019 | |
| Tesaro, INC. | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.